Sequential incretin-based therapy

Intervention1 paper2 findings

Outcomes

2

HbA1c

downin humans1Very low certainty

1 study

Sequential incretin-based therapy decreases HbA1c in humans (to 4.9% (from 8.3%)).
HumansPrader-Willi syndrome and type 2 diabetes18 monthsmalesn = 1
Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome · JCEM case reports · 16 Sep 2026

Body weight

downin humans1Very low certainty

1 study

Sequential incretin-based therapy decreases body weight in humans (-108.7 kg).
HumansPrader-Willi syndrome and type 2 diabetes18 monthsmalesn = 1
Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome · JCEM case reports · 16 Sep 2026

Latest

1

JCEM Case ReportsResearch17 Sep

Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome